Cargando…
Fluid loading in abdominal surgery - saline versus hydroxyethyl starch (FLASH Trial): study protocol for a randomized controlled trial
BACKGROUND: Inappropriate fluid therapy during surgery is associated with significant morbidity and mortality. Few studies have examined the effects of particular types of fluids (crystalloid or colloid solutions) in surgical patients, especially with the goal of hemodynamic optimization. Isotonic s...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687283/ https://www.ncbi.nlm.nih.gov/pubmed/26690683 http://dx.doi.org/10.1186/s13063-015-1085-3 |
_version_ | 1782406603321901056 |
---|---|
author | Futier, Emmanuel Biais, Matthieu Godet, Thomas Bernard, Lise Rolhion, Christine Bourdier, Justine Morand, Dominique Pereira, Bruno Jaber, Samir |
author_facet | Futier, Emmanuel Biais, Matthieu Godet, Thomas Bernard, Lise Rolhion, Christine Bourdier, Justine Morand, Dominique Pereira, Bruno Jaber, Samir |
author_sort | Futier, Emmanuel |
collection | PubMed |
description | BACKGROUND: Inappropriate fluid therapy during surgery is associated with significant morbidity and mortality. Few studies have examined the effects of particular types of fluids (crystalloid or colloid solutions) in surgical patients, especially with the goal of hemodynamic optimization. Isotonic saline is the most commonly used fluid worldwide but may be associated with potential nephrotoxicity. Hydroxyethyl starch (HES) solutions are widely used in surgical patients as a component of goal-directed fluid optimization strategies, but several large multicenter studies have suggested increased rates of acute kidney injury and adverse events with the use of HES in ICU patients. Despite what may be inferred from physiological studies, the benefit and harm of 0.9 % saline and HES during hemodynamic therapy have not been clearly established in surgical patients. METHODS/DESIGN: The FLASH trial is an investigator-initiated, prospective, multicenter, randomized, double-blinded, two-arm trial, randomizing 826 patients with moderate-to-high risk of postoperative complications to receive 6 % HES 130/0.4 or 0.9 % saline during individualized goal-directed fluid optimization. The primary outcome measure is a composite of death or major postoperative complications within 14 days following surgery. The sample size will allow the detection of a 10 % absolute between-group difference in the primary outcome measure with a type 1 error rate of 5 % and power of 95 %, assuming a 5 % mortality rate and 20 % morbidity (thus 25 % for the composite endpoint). DISCUSSION: The FLASH trial may provide important data on the efficacy and safety of commonly used fluid solutions and could have a significant impact on future treatment of surgical patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02502773. Registered 16 June 2015. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13063-015-1085-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4687283 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-46872832015-12-23 Fluid loading in abdominal surgery - saline versus hydroxyethyl starch (FLASH Trial): study protocol for a randomized controlled trial Futier, Emmanuel Biais, Matthieu Godet, Thomas Bernard, Lise Rolhion, Christine Bourdier, Justine Morand, Dominique Pereira, Bruno Jaber, Samir Trials Study Protocol BACKGROUND: Inappropriate fluid therapy during surgery is associated with significant morbidity and mortality. Few studies have examined the effects of particular types of fluids (crystalloid or colloid solutions) in surgical patients, especially with the goal of hemodynamic optimization. Isotonic saline is the most commonly used fluid worldwide but may be associated with potential nephrotoxicity. Hydroxyethyl starch (HES) solutions are widely used in surgical patients as a component of goal-directed fluid optimization strategies, but several large multicenter studies have suggested increased rates of acute kidney injury and adverse events with the use of HES in ICU patients. Despite what may be inferred from physiological studies, the benefit and harm of 0.9 % saline and HES during hemodynamic therapy have not been clearly established in surgical patients. METHODS/DESIGN: The FLASH trial is an investigator-initiated, prospective, multicenter, randomized, double-blinded, two-arm trial, randomizing 826 patients with moderate-to-high risk of postoperative complications to receive 6 % HES 130/0.4 or 0.9 % saline during individualized goal-directed fluid optimization. The primary outcome measure is a composite of death or major postoperative complications within 14 days following surgery. The sample size will allow the detection of a 10 % absolute between-group difference in the primary outcome measure with a type 1 error rate of 5 % and power of 95 %, assuming a 5 % mortality rate and 20 % morbidity (thus 25 % for the composite endpoint). DISCUSSION: The FLASH trial may provide important data on the efficacy and safety of commonly used fluid solutions and could have a significant impact on future treatment of surgical patients. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02502773. Registered 16 June 2015. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13063-015-1085-3) contains supplementary material, which is available to authorized users. BioMed Central 2015-12-21 /pmc/articles/PMC4687283/ /pubmed/26690683 http://dx.doi.org/10.1186/s13063-015-1085-3 Text en © Futier et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Study Protocol Futier, Emmanuel Biais, Matthieu Godet, Thomas Bernard, Lise Rolhion, Christine Bourdier, Justine Morand, Dominique Pereira, Bruno Jaber, Samir Fluid loading in abdominal surgery - saline versus hydroxyethyl starch (FLASH Trial): study protocol for a randomized controlled trial |
title | Fluid loading in abdominal surgery - saline versus hydroxyethyl starch (FLASH Trial): study protocol for a randomized controlled trial |
title_full | Fluid loading in abdominal surgery - saline versus hydroxyethyl starch (FLASH Trial): study protocol for a randomized controlled trial |
title_fullStr | Fluid loading in abdominal surgery - saline versus hydroxyethyl starch (FLASH Trial): study protocol for a randomized controlled trial |
title_full_unstemmed | Fluid loading in abdominal surgery - saline versus hydroxyethyl starch (FLASH Trial): study protocol for a randomized controlled trial |
title_short | Fluid loading in abdominal surgery - saline versus hydroxyethyl starch (FLASH Trial): study protocol for a randomized controlled trial |
title_sort | fluid loading in abdominal surgery - saline versus hydroxyethyl starch (flash trial): study protocol for a randomized controlled trial |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687283/ https://www.ncbi.nlm.nih.gov/pubmed/26690683 http://dx.doi.org/10.1186/s13063-015-1085-3 |
work_keys_str_mv | AT futieremmanuel fluidloadinginabdominalsurgerysalineversushydroxyethylstarchflashtrialstudyprotocolforarandomizedcontrolledtrial AT biaismatthieu fluidloadinginabdominalsurgerysalineversushydroxyethylstarchflashtrialstudyprotocolforarandomizedcontrolledtrial AT godetthomas fluidloadinginabdominalsurgerysalineversushydroxyethylstarchflashtrialstudyprotocolforarandomizedcontrolledtrial AT bernardlise fluidloadinginabdominalsurgerysalineversushydroxyethylstarchflashtrialstudyprotocolforarandomizedcontrolledtrial AT rolhionchristine fluidloadinginabdominalsurgerysalineversushydroxyethylstarchflashtrialstudyprotocolforarandomizedcontrolledtrial AT bourdierjustine fluidloadinginabdominalsurgerysalineversushydroxyethylstarchflashtrialstudyprotocolforarandomizedcontrolledtrial AT moranddominique fluidloadinginabdominalsurgerysalineversushydroxyethylstarchflashtrialstudyprotocolforarandomizedcontrolledtrial AT pereirabruno fluidloadinginabdominalsurgerysalineversushydroxyethylstarchflashtrialstudyprotocolforarandomizedcontrolledtrial AT jabersamir fluidloadinginabdominalsurgerysalineversushydroxyethylstarchflashtrialstudyprotocolforarandomizedcontrolledtrial AT fluidloadinginabdominalsurgerysalineversushydroxyethylstarchflashtrialstudyprotocolforarandomizedcontrolledtrial |